Vanguard Capital Management
SNDX icon

Vanguard Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Vanguard Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.9M Buy
3,927,892
+105,313
+3% +$2.19M ﹤0.01% 1636
2026
Q1 		$89.3M Buy
+3,822,579
New +$83.1M ﹤0.01% 1530

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management's SNDX Position: Q2 2026 in Review

Vanguard Capital Management increased its Syndax Pharmaceuticals (SNDX) stake by 2.8% in Q2 2026, buying an estimated $2.19M and bringing the position to 3,927,892 shares worth $85.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1636.

Vanguard Capital Management first reported a position in SNDX in Q1 2026 and has held it in 2 quarters since. The position peaked at $89.3M in Q1 2026. 240 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Vanguard Capital Management held 3,927,892 shares of Syndax Pharmaceuticals worth $85.9M as of Q2 2026.
  • Vanguard Capital Management bought 105,313 Syndax Pharmaceuticals shares in Q2 2026, an estimated $2.19M.
  • Syndax Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1636 holding.
  • Vanguard Capital Management first reported a position in Syndax Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Syndax Pharmaceuticals position peaked at $89.3M in Q1 2026.
  • 240 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.